Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 825 results for "daiichi sankyo"

DAIICHI SANKYO : Notice on Details of the Share Options
4 Traders

Ranbaxy is now Daiichi's

Mumbai: Japan's Daiichi Sankyo Co. has completed its $4 billion acquisition of Ranbaxy Laboratories Ltd., India's largest pharmaceutical company, the companies said Friday. Daiichi Sankyo Co. agreed to buy a controlling stake in Ranbaxy in June, and ... Pune Mirror, 1 week ago
12th Takamine Memorial Daiichi Sankyo Prize winner announced European Pharmaceutical Review, 3 weeks ago
[x]  

116 images for daiichi sankyo

4 Traders, 2 weeks ago
Bio Spectrum Asia, 2 weeks ago
Bio Spectrum Asia, 3 days ago
4 Traders, 4 weeks ago
Pharma Letter, 1 week ago
Drug Discovery and Development, 2 weeks ago
Rediff.com, 1 month ago
Rediff.com, 1 month ago
Scottrade, 2 weeks ago
Lawyers & Settlements, 1 month ago
Rediff.com

Daiichi files plea to vacate stay on Sun-Ranbaxy merger

Daiichi Sankyo, owner of Ranbaxy Laboratories Limited, has filed a petition in Andhra Pradesh High Court requesting it to vacate the 'status quo' order it issued earlier on Sun Pharma-Ranbaxy merger process.
 Money Control2 months ago Daiichi files plea in HC to vacate stay on Sun-Ranbaxy merger  Business Standard2 months ago Daiichi files plea in HC on Sun-Ranbaxy merger  Times of India2 months ago
[x]  

Daiichi Sankyo and Eli Lilly and Company: Heart patients in England and Wales offered more choice of therapies as NICE extends recommendations for prasugrel

GERRARDS CROSS, England--(BUSINESS WIRE)--Jul. 23, 2014-- Revised guidance from the National Institute for Health and Care Excellence (NICE), recommends once-daily, oral antiplatelet prasugrel (Efient), in combination with aspirin, as a ...
 BusinessWeek2 days ago Cost watchdog expands NHS use of bloodthinner Efient  Big News Network1 day ago Daiichi Sankyo, Inc. And Eli Lilly and Company: Heart Patients In England And Wales Offered More Choice Of Therapies As National Institute for Clinical Excellence (NICE) Extends Recommendations For Prasugrel  BioSpace1 day ago Heart patients in England and Wales offered more choice of therapies as NICE extends recommendations for prasugrel  FirstWord Pharma2 days ago
[x]  

Mitsubishi receives approval to manufacture and market diabetes drug

Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd. have announced that Mitsubishi has received approval to manufacture and market the SGLT2 inhibitor, CANAGLU tablets 100mg in Japan, for the treatment of patients with type 2 diabetes ...
 Individual.com1 week ago DAIICHI SANKYO -Marketing and Manufacturing Approval in Japan Received for CANAGLU Tablets 100mg  TMC Net2 weeks ago Japan marketing approval for Canaglu; Vaccine license for Daiichi Sankyo  Pharma Letter2 weeks ago Marketing and Manufacturing Approval in Japan Received for CANAGLU® Tablets 100mg  Noodls3 weeks ago

DAIICHI SANKYO : Pieris Achieves Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics

By a News Reporter-Staff News Editor at Biotech Week -- Pieris AG announced that it has achieved a second milestone for its second program, and fifth milestone overall, in its discovery and development collaboration with Daiichi Sankyo Company ...
 4 Traders3 weeks ago Pieris Furthers Daiichi Sankyo Collaboration with Validation of Anticalin Therapeutics  Individual.com4 weeks ago Pieris Achieves Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics  CNBC1 month ago DAIICHI SANKYO : Pieris Furthers Daiichi Sankyo Collaboration with Validation of Anticalin Therapeutics  4 Traders4 weeks ago
[x]  
Scottrade

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

USA-based Portola Pharmaceuticals (Nasdaq: PTLA) has entered into a second clinical collaboration agreement with Japanese drug major Daiichi Sankyo (TYO: 4568) to study andexanet alfa, Portola's investigational Factor Xa inhibitor antidote, in Phase ...
 Pharma Letter2 weeks ago Portola, Daiichi Expand Clinical Collaboration  Contract Pharma2 weeks ago Portola inks collaboration deal with Daiichi Sankyo  Seeking Alpha2 weeks ago Portola, Daiichi Sankyo collaborate for Phase III studies of factor Xa inhibitor antidote  Pharmaceutical Business Review2 weeks ago
[x]  

DAIICHI SANKYO -Announcement on obtaining in Japan the marketing and manufacturing license for the 4-valent combination vaccine for the prevention of Pertussis, Diphtheria, Tetanus and Poliomyelitis (Polio) 'Squarekids subcutaneous injection syringe'

[July 08, 2014] (ENP Newswire Via Acquire Media NewsEdge) ENP Newswire - 08 July 2014 Release date- 04072014 - Tokyo, Japan - Daiichi Sankyo Co., Ltd. (hereinafter Daiichi Sankyo) and Sanofi K.K. announce that Kitasato Daiichi ...
 TMC Net2 weeks ago DAIICHI SANKYO : Announcement on obtaining in Japan the marketing and manufacturing license for the 4-valent combination vaccine for the prevention of Pertussis, Diphtheria, Tetanus and Poliomyelitis (Polio) 'Squarekids subcutaneous injection syringe'  4 Traders2 weeks ago Announcement on obtaining in Japan the marketing and manufacturing license for the 4-valent combination vaccine for the prevention of Pertussis, Diphtheria, Tetanus and Poliomyelitis (Polio) Squarekids® subcutaneous injection syringe  Noodls3 weeks ago
[x]  

DS-5565 is an oral, small-molecule analgesic being developed by Daiichi Sankyo for the treatment of PDN

Scope - Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on DS-5565 including product description, ...
 TransWorldNews3 weeks ago

Daiichi Sankyo receives NexTEP grant to develop vaccine adjuvant

Daiichi Sankyo Company, Limited has announced that its R&D project has received a Newly extended Technology transfer Program, or NexTEP, grant from the Japan Science and Technology Agency to develop a novel, vaccine adjuvant. The development on the ...
 Individual.com1 month ago

American Regent's Injectafer® (Ferric Carboxymaltose Injection) Now the Fastest Growing IV Iron in United States

American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc. (a Daiichi Sankyo Group Company), announced today the double-digit sales growth of Injectafer ® (ferric carboxymaltose injection) in 2014, making it the ...
 Town Hall1 week ago American Regent Reports Sales Growth of Injectafer  Pharmaceutical & Medical Packaging News3 days ago American Regent's Injectafer (Ferric Carboxymaltose Injection) Now the Fastest Growing IV Iron in United States  Pharmacy Choice1 week ago American Regent's Injectafer(r) (Ferric Carboxymaltose Injection) N...  Finwin1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less